FLT3 and acute myeloid leukemia: A phase II trial explored midostaurin monotherapy in 95 R/R or newly diagnosed unfit AML patients, with the overall response rate (CR, PR, HI, BR) of 71% and 56% in FLT3-mutant group and FLT3 wild-type group, respectively [32].